Publications by authors named "C Kurzeder"
Article Synopsis
- Maintenance therapies like PARP inhibitors and bevacizumab have improved outcomes for advanced ovarian cancer patients, prompting a study to explore treatment variability across Europe.
- A Delphi study was conducted with experts to understand maintenance treatment strategies and gauge consensus on best practices.
- Key factors influencing treatment choices include tumor mutation status and perceived risk of disease progression, with high-risk cases defined by advanced FIGO stages or residual disease after initial treatment.
Article Synopsis
- The study investigates the role of BRCA promoter methylation in triple-negative breast cancer (TNBC), emphasizing its potential as an alternative to rare somatic BRCA mutations, particularly in relation to the effectiveness of PARP inhibitors.
- Researchers analyzed BRCA promoter methylation in breast cancer metastases using advanced methylation profiling and tested tumor organoids derived from these tumors for their response to PARP inhibitors.
- The findings suggest that while BRCA promoter hypermethylation is rare in metastatic breast cancer, it is preserved in xenograft models and may serve as a valuable indicator for targeted PARP inhibitor therapy.
Article Synopsis
- The DESTINY-Breast12 study is the largest prospective trial examining the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer, including those with brain metastases (BMs).
- In this study, T-DXd showed promising results, with a 12-month progression-free survival (PFS) of 61.6% for patients with BMs and an objective response rate (ORR) of 62.7% for those without BMs.
- Adverse events were observed in both cohorts, with 51% of patients with BMs and 49% of those without experiencing grade 3 or higher side effects, indicating the need for careful monitoring
Introduction: The American Society of Breast Surgeons (ASBrS) recently classified oncoplastic breast conserving surgery (OBCS) into two levels. The association of resection ratio during OBCS with patient-reported outcomes (PRO) is unclear.
Materials And Methods: Patients with stage 0-III breast cancer undergoing OBCS between 01/2011-04/2023 at a Swiss university hospital, who completed at least one postoperative BREAST-Q PRO questionnaire were identified from a prospectively maintained institutional database.